Corvus Pharmaceuticals, Inc. · NASDAQ:CRVS
Corvus Pharmaceuticals — ESMO
5 slides from Corvus Pharmaceuticals's conference presentation
Slide 1: Identification of Adenosine Pathway Genes Associated with Response to CPI-444
IDENTIFICATION OF ADENOSINE PATHWAY GENES ASSOCIATED WITH RESPONSE TO THERAPY WITH THE ADENOSINE RECEPTOR ANTAGONIST CPI-444 Presentation #:1137PD Stephen Willingham Corvus Pharmaceuticals Slides For Discussant esmo.org
Slide 2: Adenosine Signaling Through A2AR Induces a Specific Gene Signature in Human Immune Cells
Adenosine Signaling Through A2AR Induces a Specific Gene Signature in Human Immune Cells. • Extracellular adenosine within the tumor microenvironment creates an immunosuppressive niche • Extracellular adenosine has a short half life and it is not feasible to routinely measure in human tumors. • This
Slide 3: Expression of the Adenosine Signature Correlates with Tumor Regression in CPI-444 RCC Trial
Expression of the “Adenosine Signature” Correlates with Tumor Regression in Corvus’ Ongoing Ph 1/1b trial with CPI- 444 Treatment in RCC p-value = 0.0075 Adenosine signature determined in archive or pre treatment biopsy tissue
Slide 4: Adenosine Signature Is Nearly Identical To GNE Myeloid Signature
Adenosine Signature Is Nearly Identical To GNE “Myeloid Signature” That Associates with Poor Response to Atezolizumab Monotherapy in RCC Patients IMMotion150: Ph2 study of atezolizumab ± bevacizumab (anti-VEGF) versus sunitinib in 305 patients with treatment-naive metastatic RCC TeffHigh / MyeloidLo
Slide 5: Conclusions
Conclusions • A2AR agonists induce a specific gene signature in human immune cells. This “Adenosine Signature” is dominated by inflammatory myeloid cytokines and chemokines that signal through CXCR2. • Adenosine induction of these genes dampens T cell immunity and shifts the balance away from T effe